Caribbean International Holdings Appoints Leader in Stem Cell Research to Advisory Board
07 April 2014 - 11:00PM
Marketwired
Caribbean International Holdings Appoints Leader in Stem Cell
Research to Advisory Board
MIAMI, FL--(Marketwired -
April 07, 2014) - Caribbean International Holdings
(PINKSHEETS: CIHN) is excited
to announce that it has appointed Rafael Gonzalez, Ph.D to its
Advisory Board.
Dr. Gonzalez is currently responsible for the development of
clinical stem cell applications for several disease/trauma states
for DaVinci Biosciences as their VP of Research & Development.
Dr. Gonzalez is responsible for the design and execution of all
pre-clinical and clinical experiments involving adult (bone marrow,
menstrual blood, adipose) and pre-natal stem cells (neural, bone
marrow, liver, gonadal).
Steven Swank, Chairman and CEO of Caribbean International
Holdings, stated, "We are extremely excited to have Dr. Gonzalez
join our Advisory Board. This will help us achieve our goals of
bringing science and medicine together to improve the well-being
and future of patients. His knowledge in stem cell research
and development and implementing standard operating procedures will
be a tremendous benefit to our Company."
In addition to his experience in stem cell culture and biology
from human embryonic, pre-natal and adult sources, he has extensive
knowledge in degenerative disorders involving the spinal cord.
Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a
Research Scientist at PrimeGen Biotech where he was responsible for
the design and execution of experiments involving adult (bone
marrow, menstrual blood, adipose) and pre-natal stem cells (neural,
bone marrow, liver, gonadal) for potential clinical application.
Dr. Gonzalez was also responsible for developing PrimeGen's
pre-clinical stem cell/spinal cord injury model.
Dr. Gonzalez developed his thesis at the Reeve-Irvine Research
Center, University of California, Irvine, under the advisory of Dr.
Hans Keirstead, titled: "The Role of the Chemokine CXCL10 in
Secondary Degeneration Following Spinal Cord Injury." Pre-clinical
studies conducted during this time lead by Dr. Gonzalez were aimed
at reducing secondary degenerative effects. The studies conducted
by Dr. Gonzalez precipitated the start-up of Ability Biomedical, a
company that developed anti-IP10 antibody, an antibody which can be
used to treat several degenerative disorders such as multiple
sclerosis, rheumatoid arthritis, and SCI. Ability Biomedical was
purchased by Medarex in 2007, which was purchased by Bristol-Myers
Squibb that sponsors a phase II clinical trial using anti-IP10
antibody (MDX-1100). He also was involved with preclinical studies
in the development of the use of human embryonic stem cells into
spinal cord injury.
Dr. Gonzalez has several scientific publications in the field of
stem cells, spinal cord injury and the immune system.
Dr. Gonzalez received his BS in Biological Science and his Ph.D
in Anatomy and Neurobiology from the University of California,
Irvine, CA.
Dr. Gonzalez will join Frank Leiber, Ph.D on the Advisory
Board.
Dr. Leiber's first degree is in Economics and Business
Administration from HEC at the University of Lausanne. He earned
his Ph.D in Financial Econometrics at HEI - University of Geneva,
and he studied Economics and Finance on a Postgraduate Fulbright
Scholarship at the University of Chicago. Dr. Leiber is a citizen
of Luxembourg and Switzerland, and worked as a senior investment
banker on market and credit derivatives in Chicago, New York,
Zurich, Geneva and London for Morgan Guaranty, Mitsubishi Finance
International, and as a credit risk management expert for
Moody's-KMV. He consults independently on tax efficient vehicles in
Luxembourg and Switzerland, on alternative investment funds, exit
planning and business valuation, and in wealth management. He
advises on life-insurance linked structured products for HNW
individuals and families. He regularly teaches at banks around the
world and is an adjunct professor at New York University's Stern
School of Business as well as at the University of Luxembourg
School of Finance. Dr. Leiber also serves as a non-executive member
on boards of directors for several commercial and non-profit
entities.
FORWARD-LOOKING STATEMENT
This report contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
and such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation.
Contact: Caribbean International HoldingsStem Cell Marketing
Inc. DBA Regenerative BioScience2100 Constitution Blvd.Sarasota, FL
34231Corporate Office: (941)
924-9400www.regenerativebioscience.com
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Apr 2024 to May 2024
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From May 2023 to May 2024